XpresCheck™ COVID-19 Testing Facility Opens at Denver International Airport Today

Rhea-AI Summary

XpresSpa Group has opened a new XpresCheck™ COVID-19 testing facility at Denver International Airport as of December 16, 2020. This pop-up location is situated in Concourse B and features six testing rooms, with an estimated capacity of over 400 tests per day. Testing options include Rapid Molecular and PCR tests, available to all passengers and airport employees. The facility accepts various insurance plans while ensuring HIPAA compliance. This marks the company's fifth testing site and introduces a cost-effective modular approach for future rollouts.

Positive

• Opening of fifth COVID-19 testing facility at Denver International Airport.
• Facility capacity to administer over 400 tests per day, enhancing service availability.
• Testing options include Rapid Molecular and PCR tests, catering to diverse passenger needs.
• Modular construction method reduces costs for future facility rollouts.

Negative

• None.

Located within Concourse B, Post Security

DENVER, Dec. 16, 2020 (GLOBE NEWSWIRE) -- XpresSpa Group, Inc. (Nasdaq: XSPA) (“XpresSpa” or the “Company”), a health and wellness company, in conjunction with Denver International Airport (DEN), announces the opening of an XpresCheck™ COVID-19 testing facility at Denver International Airport today.

This XpresCheck is a pop-up facility in the center of Concourse B, post-security. The facility has six separate testing rooms with an anticipated capacity to administer over 400 tests per day.

COVID-19 testing options will include the Rapid Molecular COVID-19 Test and the Polymerase Chain Reaction (PCR) Test. These services will be available to all airline passengers as well as all airport employees, including airline employees, contractors and workers, concessionaires and their employees, TSA officers, and U.S. Customs and Border Protection (CPB) agents. All insurance plans are accepted outside of network and all information will remain private and HIPAA-compliant.

"The XpresCheck opening at Denver International Airport marks our fifth COVID-19 testing facility and first pop-up location,” said Doug Satzman, XpresSpa CEO. “Given the spike in cases across the country, it is more important than ever that there is reliable COVID-19 testing for airport employees and the traveling public and we therefore look forward to providing this important service to customers. Our new pop-up building methodology will also enable us to accelerate XpresCheck’s rollout to additional airports at a lower cost than our original modular constructed facilities.”

“We are excited to welcome XpresCheck to Denver and the opportunity for COVID-19 testing at the airport,” said DEN CEO Kim Day. “The health and safety of our passengers has been, and remains, our top priority and further testing opportunities furthers our efforts to provide a safe passenger experience.”

About XpresSpa Group, Inc.

XpresSpa Group, Inc. (Nasdaq: XSPA) is a leading global health and wellness holding company. XpresSpa Group’s core asset, XpresSpa, is a leading airport retailer of spa services and related health and wellness products, with 50 locations in 25 airports globally. Through its XpresTest, Inc. subsidiary, the Company also provides COVID-19 screening and testing under its XpresCheck™ brand at JFK International Airport, Newark Liberty International Airport, Logan International Airport, Sky Harbor International Airport, and Denver International Airport. To learn more about XpresSpa Group, visit: www.XpresSpaGroup.com. To learn more about XpresSpa, visit www.XpresSpa.com. To learn more about XpresCheck, visit www.XpresCheck.com.

About Denver International Airport

Denver International Airport is the fifth-busiest airport in the United States, with more than 69 million passengers traveling through the airport in 2019. DEN is the primary economic engine for the state of Colorado, generating more than $33 billion for the region annually. For more information, visit www.FlyDenver.com.

Forward-Looking Statements
This press release may contain "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934. These include statements preceded by, followed by or that otherwise include the words "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. In particular, these statements include, without limitation, statements about our expectations relating to our new XpresCheck™ concept, being able to expand testing to other communicable diseases as well as administer vaccinations for the seasonal flu, our positioning to be part of the national rollout of a COVID-19 vaccination when it becomes available (including whether such vaccination becomes available in the near term or at all), the degree to which our public testing model assists passengers meet testing requirements in select states and countries, our ability to identify and gain access to the latest and best COVID-19 testing methodologies and equipment, and our ability further expand our initial sites, and our overall ability to manage the regulatory challenges associated with this business line. Forward-looking statements relating to expectations about future results or events are based upon information available to XpresSpa Group as of today's date and are not guarantees of the future performance of the company, and actual results may vary materially from the results and expectations discussed. Additional information concerning these and other risks is contained in XpresSpa Group’s most recently filed Annual Report on Form 10-K, Quarterly Report on Form 10-Q, recent Current Reports on Form 8-K and other Securities and Exchange Commission filings. All subsequent written and oral forward-looking statements concerning XpresSpa Group, or other matters and attributable to XpresSpa Group or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. XpresSpa Group does not undertake any obligation to publicly update any of these forward-looking statements to reflect events or circumstances that may arise after the date hereof.

Investor Relations:
ICR
Raphael Gross
ir@xpresspagroup.com
(203) 682-8253

Media
Julie Ferguson
Julie@jfprmedia.com
(312) 385-0098

FAQ

What is XpresSpa Group's recent announcement regarding COVID-19 testing?

XpresSpa Group has opened a new XpresCheck™ COVID-19 testing facility at Denver International Airport, marking its fifth testing site.

Where is the XpresCheck™ facility located?

The XpresCheck™ facility is located in Concourse B, post-security, at Denver International Airport.

What types of COVID-19 tests are offered at the XpresCheck™ facility?

The facility offers Rapid Molecular and Polymerase Chain Reaction (PCR) tests.

What is the capacity of the Denver XpresCheck™ testing facility?

The facility has a capacity to administer over 400 tests per day.

Who can access the testing services at Denver International Airport?

Testing services are available to all airline passengers and airport employees, including TSA officers and U.S. Customs agents.